AR003959A1 - Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. - Google Patents

Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.

Info

Publication number
AR003959A1
AR003959A1 ARP960103028A AR10302896A AR003959A1 AR 003959 A1 AR003959 A1 AR 003959A1 AR P960103028 A ARP960103028 A AR P960103028A AR 10302896 A AR10302896 A AR 10302896A AR 003959 A1 AR003959 A1 AR 003959A1
Authority
AR
Argentina
Prior art keywords
prepare
stable hydrazone
elements
biologically active
reagent
Prior art date
Application number
ARP960103028A
Other languages
English (en)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of AR003959A1 publication Critical patent/AR003959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención provee nuevos reactivos para la preparación de agentes radiofarmacéuticos útiles como agentes de producción de imágenes para eldiagnóstico de afecciones cardiovasculares, infecciones, inflamaciones y cáncer; conjuntos dee lementos(kits) que comprenden dichos activos y compuestosintermediarios útiles para la preparación de dichos reactivos. Los reactivos comprenden moléculas biológicamente activas modificadas por una hidrazonaestable que reaccionan conradioisótopos que emiten rayos gamma formando agentes radiofarmacéuticos que se localizan selectivamente en las zonas deenfermedad y de este modo permiten la obtención de una imagen de dicha zona usando centellografía gamma.
ARP960103028A 1995-06-07 1996-06-07 Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. AR003959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/476,296 US5750088A (en) 1993-03-30 1995-06-07 Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals

Publications (1)

Publication Number Publication Date
AR003959A1 true AR003959A1 (es) 1998-09-30

Family

ID=23891282

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103028A AR003959A1 (es) 1995-06-07 1996-06-07 Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.

Country Status (29)

Country Link
US (2) US5750088A (es)
EP (1) EP0832068B1 (es)
JP (1) JPH11507364A (es)
KR (1) KR19990022573A (es)
CN (1) CN1192733A (es)
AR (1) AR003959A1 (es)
AT (1) ATE233241T1 (es)
AU (1) AU718683B2 (es)
BR (1) BR9609003A (es)
CA (1) CA2222183A1 (es)
CZ (1) CZ380197A3 (es)
DE (1) DE69626392T2 (es)
EA (1) EA000742B1 (es)
EE (1) EE9700313A (es)
ES (1) ES2193245T3 (es)
HR (1) HRP960250A2 (es)
HU (1) HUP9901469A3 (es)
IL (1) IL118468A0 (es)
LT (1) LT4380B (es)
LV (1) LV12044B (es)
MX (1) MX9709126A (es)
MY (1) MY133974A (es)
NO (1) NO975678L (es)
NZ (1) NZ310799A (es)
PL (1) PL323995A1 (es)
SI (1) SI9620076B (es)
SK (1) SK163497A3 (es)
WO (1) WO1996040637A1 (es)
ZA (1) ZA964854B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507233A (ja) * 1996-03-13 2000-06-13 デュポン ファーマシューティカルズ カンパニー 新規の三元複合体放射性薬剤
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
DE69722038T2 (de) * 1996-10-07 2004-02-19 Bristol-Myers Squibb Pharma Co. Radiopharmazeutische mittel zur bildgebung von infektionen und entzündungen
US6416733B1 (en) 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en) * 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
EP1068222A1 (en) * 1998-04-03 2001-01-17 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) * 1998-10-13 2000-06-30 Du Pont Pharm Co A process for the preparation of a thrombus imaging agent
CA2349333A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
IL142958A0 (en) 1998-12-18 2002-04-21 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
AU4027800A (en) * 1999-03-26 2000-10-16 Du Pont Pharmaceuticals Company Method for localization of blood clots
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
US6534038B2 (en) 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
WO2002036173A2 (en) * 2000-11-03 2002-05-10 Bristol-Myers Squibb Pharma Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
HUP0401904A3 (en) * 2001-08-08 2009-01-28 Bristol Myers Squibb Pharma Co Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
CA2783275A1 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
WO2007005491A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
WO2007046411A1 (ja) * 2005-10-19 2007-04-26 Dainippon Sumitomo Pharma Co., Ltd. イソキサゾール化合物の安定化方法
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
WO2007073283A1 (en) * 2005-12-20 2007-06-28 Astrazeneca Ab Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
MY179093A (en) 2008-12-29 2020-10-27 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
PL2382215T3 (pl) * 2008-12-29 2015-01-30 Sanofi Sa Pochodne 2-pirydyny-2-ylo-pirazol-3(2H)-onu, ich wytwarzanie i zastosowanie terapeutyczne
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) * 2019-11-22 2022-11-22 华东理工大学 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
CA1300608C (en) * 1985-05-10 1992-05-12 Edward A. Deutsch 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
GB8624272D0 (en) * 1986-10-09 1986-11-12 Amersham Int Plc Cationic complexes of tc-99m
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
AU639409B2 (en) 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
AU619538B2 (en) * 1988-03-09 1992-01-30 Cis Bio International Preparation of nitruro compounds usable as radio-pharmaceutical products
GB8808414D0 (en) * 1988-04-11 1988-05-11 Amersham Int Plc Ligands & cationic complexes thereof with technetium-99m
JPH03505087A (ja) 1988-04-29 1991-11-07 ニュー　イングランド　ディーコネス　ホスピタル　コーポレイション ハイブリッドペプチド及びその使用方法
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
WO1990003391A1 (en) 1988-09-29 1990-04-05 Biogen, Inc. Hirudin peptides
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) * 1989-02-03 1989-03-22 Amersham Int Plc Cationic complexes of technetium-99m
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US4957728A (en) * 1989-05-19 1990-09-18 University Of Cincinnati Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0410537A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
GB8919488D0 (en) * 1989-08-29 1989-10-11 Amersham Int Plc New cores for technetium radiopharmaceuticals
ZA907743B (en) 1989-10-03 1991-07-31 Merrell Dow Pharma Radiolabeled anticoagulant peptides
US5086069A (en) 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) * 1990-07-04 1992-01-10 Cis Bio Int Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
EP0570493B1 (en) 1991-02-08 2000-01-05 Diatide, Inc. TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
ES2150945T3 (es) 1992-05-21 2000-12-16 Diatide Inc Peptidos marcados con tecnecio-99m para obtencion de imagenes de trombos.
GB2268494B (en) 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
FR2698272B1 (fr) * 1992-11-20 1994-12-30 Cis Bio Int Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
EP0832068B1 (en) 2003-02-26
NO975678D0 (no) 1997-12-05
SI9620076B (sl) 2000-02-29
NO975678L (no) 1998-02-06
DE69626392D1 (de) 2003-04-03
CN1192733A (zh) 1998-09-09
SK163497A3 (en) 1998-10-07
EE9700313A (et) 1998-06-15
US6015904A (en) 2000-01-18
ATE233241T1 (de) 2003-03-15
ES2193245T3 (es) 2003-11-01
JPH11507364A (ja) 1999-06-29
HRP960250A2 (en) 1997-12-31
EP0832068A1 (en) 1998-04-01
LV12044B (en) 1998-09-20
LT4380B (lt) 1998-09-25
BR9609003A (pt) 1999-12-14
HUP9901469A3 (en) 2000-02-28
LV12044A (lv) 1998-05-20
US5750088A (en) 1998-05-12
KR19990022573A (ko) 1999-03-25
AU6166196A (en) 1996-12-30
ZA964854B (en) 1997-12-08
EA199800025A1 (ru) 1998-06-25
MY133974A (en) 2007-11-30
DE69626392T2 (de) 2004-04-22
HUP9901469A2 (hu) 1999-08-30
AU718683B2 (en) 2000-04-20
MX9709126A (es) 1998-03-31
CA2222183A1 (en) 1996-12-19
WO1996040637A1 (en) 1996-12-19
PL323995A1 (en) 1998-04-27
LT97191A (en) 1998-04-27
CZ380197A3 (cs) 1998-07-15
IL118468A0 (en) 1996-09-12
EA000742B1 (ru) 2000-02-28
SI9620076A (sl) 1998-08-31
NZ310799A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
AR003959A1 (es) Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.
ES2179196T3 (es) Complejos radiofarmacos ternarios.
CL2004001128A1 (es) Compuestos derivados de halogenopirimidinas aril eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida.
BR0210713A (pt) Processo para a produção de um traçador 18f-rotulado, composto, kit radiofarmacêutico, cartucho para um kit radiofarmacêutico, e, método para obtenção de uma imagem de pet diagnóstica
CY1106860T1 (el) Δομες χρωστικων ευαισθητες σε οξεα και διασπωμενες ενζυμικα για τη διαγνωστικη με ακτινοβολια εγγυς υπερυθρου και για τη θεραπεια
DK0684843T3 (da) Technetium-99m-mærkede peptider til diagnostisk billeddannelse af inflammation
BR9607933A (pt) Reagente para preparar um radiofarmacêutico agente de formação de imagem cintigráfica e radioterapêutico complexo composição kit para preparar uma preparação radiofarmacêutica processo para rotular um reagente para formar uma imagem de um sítio e para fazer um reagente composição de matéria e uso do reagente
ATE28569T1 (de) Zusammensetzung, die einen radiomarkierten antikoerper enthaelt, ausruestung zu ihrer herstellung und ausruestung zur krebs- oder tumorbestimmung, die diese zusammensetzung enthaelt.
Washburn et al. DL-[Carboxyl-11C] tryptophan, a potential agent for pancreatic imaging; production and preclinical investigations
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
BR0314716A (pt) Anticorpos de subunidade alfa de lfa-1 e métodos de uso
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
Pallares et al. Development of an actinium-225 radioimmunoconjugate for targeted alpha therapy against SARS-CoV-2
DK0788377T3 (da) Radiomærkede glucaner
WATANABE et al. Disposition of fractionated 3H-heparin in rats
Nguyen et al. Efficacy of nimotuzumab (hR3) conjugated with 131I or 90Y in laryngeal carcinoma xenograft mouse model
BR0108609A (pt) Anticorpo com especificidade pelo câncer de cólon
CO2021017708A2 (es) Ligandos de antígeno de membrana específico de próstata (psma) y sus usos
DE60206599D1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
BR9913627A (pt) Uso de um derivado de antraciclina para o tratamento de um tumor no fìgado
WO2019204432A3 (en) Fluorine-18 labeled compositions and their use in imaging of biological tissue
AU2000263935A1 (en) Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
DK0750610T3 (da) Piperidyl-4-substituerede tyrosinderivater som scintigrafiske billedfrembringende midler til diagnose af thrombose
ES2093135T3 (es) Anticuerpos monoclonales contra el complejo plasmina-antiplasmina, procedimiento para su preparacion asi como su utilizacion.
AR006192A1 (es) Complejos radiofarmaceuticos y conjunto de elementos para preparar dichos complejos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal